加载中
NASDAQHealthcareBiotechnology
最新数据
US$3.89
+US$0.01 · +0.26%
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
前收盘价
US$3.89
+US$0.01 · +0.26%
盘中时间采用ET。市场数据可能有所延迟。
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
日内区间
当前US$3.89
52周区间
当前US$3.89
盘中时间采用ET。市场数据可能有所延迟。
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
日内区间
当前US$3.89
52周区间
当前US$3.89
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1214万 USD | 700万 USD | — | — | — |
| 销货成本 | 171.1万 USD | — | — | — | — |
| 毛利 | 1042.9万 USD | 700万 USD | — | — | — |
| 研究与开发 | 9430万 USD | 1.18亿 USD | 1.03亿 USD | 9288.9万 USD | 8677.8万 USD |
| 销售、一般及管理费用 | 2240.6万 USD | 2871.9万 USD | 2888.4万 USD | 3065.1万 USD | 2695.7万 USD |
| 营业费用 | 1.15亿 USD | 1.47亿 USD | 1.32亿 USD | 1.24亿 USD | 1.14亿 USD |
| 折旧和摊销 | 171.1万 USD | 177.2万 USD | 116.9万 USD | 132.4万 USD | 91.5万 USD |
| 营业利润 | −1.05亿 USD | −1.4亿 USD | −1.32亿 USD | −1.24亿 USD | −1.14亿 USD |
| 净利润 | −9949.8万 USD | −1.27亿 USD | −1.22亿 USD | −1.15亿 USD | −1.12亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$8.00
上涨空间 105.66%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI847.74万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM280.55万0.00%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF256.68万0.00%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO100.78万0.01%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO89.68万0.00%180亿 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC34.22万0.03%13.17亿 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM23万0.20%1.17亿 USD0.73%US$15.9402+0.25%
Vanguard Russell 2000 Growth ETFVTWG16.88万0.01%17亿 USD0.06%US$260.49+0.91%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Growth ETFVTWGAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
